INS and Hypoglycemia: The pharmacokinetics and pharmacodynamics of current rapid-acting insulins limit the closed-loop system's ability to mitigate immediate post-prandial hyperglycaemia (41), and the resultant increase in algorithm-driven insulin delivery increases the risk of delayed hypoglycaemia.